Podiatrist Loses DEA Registration Over State License Issue
Published Date: 6/24/2026
Notice
Summary
Irina Gross, a podiatrist from Ohio, lost her DEA registration because she no longer has the state permission to handle controlled substances. She didn’t ask for a hearing, so the DEA canceled her registration by default. This means she can’t legally prescribe or manage controlled drugs anymore, effective immediately, impacting her medical practice and patients.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
DEA Registration Revoked for Named Podiatrist
The Drug Enforcement Administration revoked DEA Certificate of Registration No. FG2593487 issued to Irina Gross, D.P.M., because she no longer has state authority to handle controlled substances. The revocation is effective July 24, 2026; her Ohio DPM and RCP licenses were suspended effective June 11, 2025 and are recorded as permanently revoked in Ohio online records.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-12654 — Schedules of Controlled Substances: Temporary Placement of O-Desmethyltramadol in Schedule I
Starting July 24, 2026, O-desmethyltramadol (also called O-DSMT) will be temporarily placed in Schedule I, meaning it’s treated like the most tightly controlled drugs. This affects anyone who makes, sells, studies, or even just possesses it, bringing strict rules and penalties. The move aims to keep people safe while the government studies the drug more closely.
2026-12653 — Schedules of Controlled Substances: Placement of Bromazolam in Schedule I; Correction
The DEA fixed a typo in the official chemical name of bromazolam, a drug they put in the strictest Schedule I category starting March 16, 2026. This correction makes the rules clear for everyone involved, especially law enforcement and drug handlers. No new fees or deadlines, just a clean-up to keep things accurate and official.
2026-12140 — Importer of Controlled Substances Application: Scottsdale Research Institute
Scottsdale Research Institute wants to become an official importer of some controlled substances like ibogaine and marijuana. People who make or import these drugs can share their thoughts or ask for a hearing by July 17, 2026. This move could affect how these substances are brought into the U.S., but no costs or fees are mentioned yet.
2026-12143 — Importer of Controlled Substances Application: AndersonBrecon, Inc. DBA PCI Pharma Services
AndersonBrecon, Inc. DBA PCI Pharma Services wants to become an official importer of certain controlled substances, including some strong drugs like tetrahydrocannabinols. People and companies involved with these drugs can share their thoughts or ask for a hearing by July 17, 2026. This move could impact how these substances are brought into the U.S., but no costs or fees were mentioned yet.
Previous / Next Documents
Previous: 2026-12649 — Uniform Formulary Beneficiary Advisory Panel; Notice of Federal Advisory Committee
The Department of Defense is holding a public meeting on June 22, 2026, to discuss updates to the Uniform Formulary, which affects military health beneficiaries and their medication options. This meeting will review recommendations that could change which medicines are covered, potentially impacting costs and access. Anyone interested can join by phone and share their thoughts, making it a great chance to have a say in military healthcare decisions.
Next: 2026-12651 — Certain Frozen Fish Fillets From Vietnam; Determination
The U.S. International Trade Commission decided to keep the extra taxes on frozen fish fillets from Vietnam because removing them could hurt American fish businesses. This means importers will still pay these duties, helping protect U.S. jobs and companies. The decision was finalized in June 2026 and affects anyone buying or selling these fish fillets in the U.S.